For example, CYP2D6 polymorphism is involved in tamoxifen variability among patients with breast cancer, since CYP2D6 is involved in tamoxifen metabolization to 4-hydroxytamoxifen and endoxifen, both of which display higher anti-estrogenic activity [93]. This evidence concerns the gene CYP2D6 and breast carcinoma.